Hanmi Pharmaceutical Co Ltd

New
Hanmi has shown remarkable growth since its foundation in 1973 and has now become the most spotlighted company among Korean pharmaceutical companies. We are proud to be known as a global leader in the quality API production of cephalosporins, cardiovascular, anti-diabetics, gastrointestinal, and CNSs. The facilities have been inspected and approved by UK MHRA, German BSG, Australian TGA, and US FDA. Hanmi has been successfully developed and marketed New Combination drug and a series of IMDs with its own patented process, and also succeeded in developing LAPSCOVERY technology, which is enhancing the half-life time for bio-products.
Location: 
Sub-event: CPHI

Contact details

14 Wiryeseong-daero
Songpa-gu
138-724
Seoul
South Korea